Thalassemia: Nursing

1,026views

Thalassemia: Nursing

Exam 1

Exam 1

Systemic lupus erythematosus (SLE): Nursing
Human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS): Nursing
Klinefelter syndrome
Disorders of sex chromosomes: Pathology review
Cell membrane
Mitosis and meiosis
Metaplasia and dysplasia
Hyperplasia and hypertrophy
Selective permeability of the cell membrane
Endocytosis and exocytosis
Glycolysis
Free radicals and cellular injury
Atrophy, aplasia, and hypoplasia
Necrosis and apoptosis
Body fluid compartments
Prader-Willi syndrome
Potassium homeostasis
Sodium homeostasis
Phosphate, calcium and magnesium homeostasis
Complete metabolic panel (CMP) - Chloride: Nursing
Acid-base map and compensatory mechanisms
Metabolic acidosis
Metabolic alkalosis
Respiratory acidosis
Respiratory alkalosis
Gene regulation
Mendelian genetics and punnett squares
Transcription of DNA
Translation of mRNA
DNA mutations
Nuclear structure
Turner syndrome
Down syndrome (Trisomy 21)
Edwards syndrome (Trisomy 18)
Patau syndrome (Trisomy 13)
Huntington disease: Nursing
T-cell development
B-cell development
Antibody classes
Introduction to the immune system
Immune response - Adaptive: Nursing
Cell-mediated immunity of natural killer and CD8 cells
Hypersensitivity reactions - Type I: Nursing
Hypersensitivity reactions - Type III: Nursing
Hypersensitivity reactions - Type IV: Nursing
Hypersensitivity reactions - Type II: Nursing
Shock - Anaphylactic: Nursing
Anaphylaxis: Nursing process (ADPIE)
Autoimmunity: Nursing
Immunodeficiency disorders - Secondary: Nursing
Immunodeficiency disorders - Primary: Nursing
HIV (AIDS)
Oncogenes and tumor suppressor genes
Biology of cancer: Nursing
Blood components
Erythropoietin
Coagulation (secondary hemostasis)
Platelet plug formation (primary hemostasis)
Anemia - Iron-deficiency: Nursing
Anemia - Aplastic: Nursing
Pernicious anemia: Year of the Zebra
Anemia of chronic disease: Year of the Zebra
Anemia - Macrocytic: Nursing
Polycythemia vera (NORD)
Polycythemia: Nursing
Thrombocytopenia: Nursing
Essential thrombocythemia (NORD)
Disseminated intravascular coagulation (DIC): Nursing
Thrombosis syndromes (hypercoagulability): Pathology review
Infectious mononucleosis: Nursing
Leukemia: Nursing process (ADPIE)
Lymphoma - Hodgkin and non-Hodgkin: Nursing
Multiple myeloma: Nursing
Hemolytic disease of the fetus and newborn: Nursing
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Sickle cell disease (NORD)
Sickle cell disease: Nursing process (ADPIE)
Thalassemia: Nursing
Hemophilia: Nursing process (ADPIE)
Hemophilia: Year of the Zebra
Immunoglobulins: Nursing pharmacology

Transcript

Watch video only

Thalassemia refers to a set of genetic disorders characterized by mutations in the hemoglobin gene. This impairs the function and number of red blood cells, ultimately causing anemia. There are two primary types of thalassemia: alpha thalassemia and beta thalassemia, both of which can have minor or major versions.

Now, let’s quickly review the physiology of red blood cells and hemoglobin. Red blood cells, or RBCs are small, round cells that are responsible for delivering oxygen and removing carbon dioxide throughout the body. They are produced in the bone marrow, in a process called erythropoiesis; then, they move around the blood for about 120 days and finally, they are destroyed by the spleen, in a process called hemolysis.

Now, inside each RBC, there are millions of hemoglobin molecules. Hemoglobin is a compound protein made up of heme and globin. Specifically, adult hemoglobin is made up of four globin chains, two alpha and two beta, and each of these proteins contains a heme group in the middle.

Heme is a ring-shaped structure, and it’s the home of one iron ion that can attach to oxygen. So at the end of the day, it’s hemoglobin that makes it possible for RBCs to perform their main role, which is oxygen transport. Finally, when red blood cells are destroyed, the heme is further broken down in the liver into bilirubin, which is subsequently excreted, while the iron is stored in the liver for future use.

Now, thalassemias are caused by an inherited DNA mutation in the genes that code for the hemoglobin alpha or beta subunits. So, clients at higher risk of thalassemia include those with a positive family history; as well as people from ethnic groups with a higher prevalence of thalassemia, like those originating from the area around the Mediterranean sea, the Middle East, India, Pakistan and Africa. Now, pathology-wise, thalassemia starts with a genetic mutation in the genes for the alpha or beta globins, that’s inherited in an autosomal recessive pattern. This causes reduced synthesis of the corresponding globin, if only one gene is mutated, or absent synthesis, if both genes are mutated. The first scenario causes thalassemia minor, while the later causes thalassemia major.

What is more, when alpha globin chains are affected, alpha thalassemia develops, and when beta globin chains are affected, that causes beta thalassemia.

So far so good. Now, with reduced or absent globin production, the resulting hemoglobin molecule is abnormal. As a consequence, abnormal RBCs are also produced in the bone marrow, and some of them are destroyed before they even make it into the circulation. This is called ineffective erythropoiesis, and it’s one thing that makes RBC levels low in thalassemia. The other factor is that mature RBCs that do make it into the circulation are also destroyed more quickly by the spleen, so there’s increased hemolysis. As a consequence, anemia develops, because there aren’t enough RBCs to deliver oxygen to all the tissues in the body.

As a compensatory mechanism, the bone marrow can increase RBC production, and it becomes packed with immature RBC precursors, which cause bone marrow hyperplasia.

Additionally, the body can increase RBC production in extramedullary sites, so in places other than the bone marrow, such as the liver. This makes the liver enlarge, causing hepatomegaly. However, these new red blood cells are frequently fragile and immature, so they’re also destroyed quickly by the spleen. All this overwork can also make the spleen enlarge, which is called splenomegaly.

Additionally, increased breakdown of RBCs causes increased breakdown of hemoglobin. This leads to a buildup of bilirubin in the blood, which causes jaundice. Excess bilirubin can also deposit and condense in the gallbladder, causing cholelithiasis, which is really just a fancy term for gallstones. Finally, iron overload, or hemochromatosis, either from excessive RBC breakdown or from transfusions done to treat the anemia, can also make iron pile up in different organs, affecting their function.

For example, when iron accumulates in the heart, it can cause cardiomyopathy, arrhythmias, hypertension, or cardiac failure. Iron overload can also contribute to osteoporosis; peripheral neuropathy; and affect endocrine glands like the thyroid, causing hypothyroidism; or the pancreas, causing diabetes mellitus. Alright, now let’s translate that into a clinical picture of thalassemia. Thalassemia minor is typically asymptomatic, while in thalassemia major, signs and symptoms may appear in children by age two.

Manifestations often include general weakness, fatigue, slow growth, pale skin or jaundice, as well as dark urine. The characteristic appearance in children is a prominent forehead, which is called frontal bossing, along with wide-set eyes, a flat nose, and maxillary prominence. Clinical assessment can reveal hepatomegaly, splenomegaly, or both.

Clinical manifestations of complications can include fractures, in case of osteoporosis; diminished sensitivity in case of peripheral neuropathy; as well as weight gain, fatigue and hair and skin changes with hypothyroidism, or polyuria, polydipsia, polyphagia and weight loss with diabetes mellitus.

The diagnosis of thalassemia starts with the client’s history and medical assessment. Blood tests typically include a complete blood count or CBC which often shows low hemoglobin and low mean corpuscular volume, which translates as microcytic anemia. A peripheral blood smear can also show microcytic and hypochromic red blood cells. Iron studies are done to rule out iron deficiency anemia, as well as check for iron overload; and hemoglobin electrophoresis can be done for DNA analysis to confirm a genetic mutation. Of note, for a baby at risk for thalassemia, genetic testing of the amniotic fluid can diagnose the condition before birth.

Treatment is typically only required for thalassemia major, and includes frequent blood transfusions, to correct the anemia, followed by chelation therapy with medications like desferrioxamine or deferasirox, to remove the excess iron from the blood transfusions. In children with severe symptoms, a stem cell transplant can be done to eliminate the need for frequent transfusions.

Surgery can also help! For example, a cholecystectomy can be done in clients with cholelithiasis, and a splenectomy may be necessary for clients with a very enlarged spleen. Bear in mind, though, that after a splenectomy, a client is at higher risk of developing infections, especially with bacteria like Streptococcus pneumoniae or Neisseria meningitidis.

Finally, gene therapy or genome editing is an emerging treatment that could be utilized to alter the blood stem cell genes to produce normal globin, but more research is needed in the field.

Key Takeaways

Thalassemia is a genetic disorder characterized by abnormal hemoglobin production, which can cause anemia and other complications. There are two main types of thalassemia: alpha and beta-thalassemia. Alpha thalassemia occurs when the body has a defect in the production of alpha-globin chains, while beta thalassemia occurs when there is a defect in the production of beta-globin chains.

Risk factors include clients with a family history of thalassemia and ethnic groups originating from places where there's a high prevalence of thalassemias, like the area around the Mediterranean sea, the Middle East, India, Pakistan, and Africa. The severity of thalassemia can vary from mild to severe, depending on the specific type and the number of gene mutations involved. Individuals with mild thalassemia may not experience any symptoms or may have mild anemia, while those with severe thalassemia can experience more severe symptoms, such as fatigue, shortness of breath, and jaundice.

Treatment is typically only required for thalassemia major and includes frequent blood transfusions to correct the anemia, followed by chelation therapy with medications like desferrioxamine or deferasirox, to remove the excess iron from the blood transfusions. In some cases, a stem cell transplant can eliminate the need for frequent transfusions; and splenectomy may also be required for clients with a very enlarged spleen. Priority goals of nursing care centers on monitoring and managing hemoglobin and iron levels. Client and family education focuses on learning about the condition, managing symptoms of anemia, and when to contact the healthcare provider.